Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

  • The PLOS ONE Staff

The Data Availability statement for this paper is incorrect. The publisher apologizes for the error. The correct statement is: Data are available upon request at vivli.org. Access to the data is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org. In your request, please include the following accession/reference numbers so that we can identify the dataset you're trying to access: NCT01246986.

Reference

  1. 1. Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, et al. (2020) Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS ONE 15(3): e0222259. https://doi.org/10.1371/journal.pone.0222259 pmid:32210440